Connect with us

Hi, what are you looking for?


S.Korea’s Genexine signs COVID-19 vaccine candidate manufacturing deal with Hanmi

SEOUL – Genexine Inc has signed a manufacturing deal for its COVID-19 vaccine candidate with Hanmi Pharm Co Ltd as it prepares to seek emergency use approval of the shot in South Korea and Indonesia, Genexine said on Tuesday.

Hanmi will begin producing 10 million doses of Genexine’s experimental COVID-19 vaccine in its biotech plant in Pyeongtaek, with an aim to gradually ramp up production capacity to millions of doses by 2022, Genexine said in a statement.

Hanmi said in a separate statement that the contract was worth 24.5 billion won ($22 million) and will be followed by additional supply deals.

Genexine is running a Phase 2a clinical trial of the experimental vaccine in South Korea on 150 healthy participants and plans global trials starting in Indonesia, the company said.

The company’s GX-19N COVID-19 vaccine candidate is a DNA based vaccine and showed no severe side effects.

In April, the vaccine developer signed a deal to supply 10 million doses of its vaccine to private Indonesian pharmaceutical firm Kalbe Farma.

Shares in Genexine were up 15% and Hanmi Pharm was up 5.3% as of 0250 GMT, outperforming a 1.1% rise in the wider market. – Reuters

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!



Almost one in five UK workers say they are likely to change jobs in the next 12 months as they seek better pay and...


Around 57 per cent of van owners feel discouraged from going electric due to a lack of charging points, according to a survey published...


Business and cycling groups have urged the government to reform its cycle to work scheme so it can be used by lower-paid and self-employed...


Beer drinkers could soon find it difficult to buy their favourite bottled beverage because of a shortage of glassware triggered by soaring energy costs,...


  Spotlight is BusinessWorld’s sponsored section that allows advertisers to amplify their brand and connect with BusinessWorld’s audience by enabling them to publish their...


Notice of Annual Stockholders’ Meeting Notice is hereby given that the Annual Stockholders Meeting will be held on Monday, June 20, 2022 at 8:30...

You May Also Like


Having a good Instagram marketing agency to back up your Instagram account is an absolute must going into the new year. With competition stronger...


Ivermectin, an existing drug against parasites including head lice, has had a checkered history when it comes to treating COVID-19. The bulk of studies...


Insomnia is the most common sleep disorder in the global population. Therefore, it is a problem that many people suffer or have suffered throughout...


As a traditionally rigid insurance industry becomes bogged down by antiquated processes and operations, a handful of industry leaders are seeking to shake things...

Disclaimer:, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartRetirementReport. All Rights Reserved.